TKIs Can Effectively Treat Post-Transplant Relapse Risk in Patients with Ph+ ALL

Researchers analyzing prospective data from two consecutive clinical trials have demonstrated that patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) with measurable pre-transplant levels of minimal residual disease (MRD) have a significantly higher risk of relapse. However, by administering post-transplantation tyrosine kinase inhibitors (TKIs), 5-year disease-free survival and overall survival were comparable in MRD-positive and -negative patients.

The researchers analyzed transplant outcomes of 65 Ph+ ALL patients in first complete remission treated with chemotherapy and imatinib. Twenty-four patients (37%) achieved a complete or major molecular response at time of conditioning, and 41 (63%) remained MRD positive.

Based on pre-transplant measurement, MRD-negative patients had significantly lower rates of relapse compared with MRD-positive patients: 8% vs. 39%, respectively (p=0.007). However, at 5-years post-transplant and with the use of TKIs, no differences in disease-free survival (58% vs. 41%,p=0.17) and overall survival (58% vs. 49%, p=0.55) were found for MRD-negative compared with MRD-positive patients.

The researchers concluded that achieving a complete molecular remission before transplantation “reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.”

Lussana F, et al. Biol Blood Marrow Transplant

Related Resource